Pfizer paid $500 million up front, a combination of cash and stock. It’s also on the hook to pay New Haven, Connecticut-based Biohaven up to $740 million in milestone payments plus royalties ...

Pfizer Inc. agreed to buy the rest of Biohaven Pharmaceutical Holding Co. for about $11.6 billion, deploying its pile of cash earned from Covid-19 sales to acquire a new migraine drug.

Pfizer Inc. said Tuesday it has entered a definitive agreement to acquire Biohaven Pharmaceutical Holding Company Ltd. for $11.6 billion in cash. Biohaven is the maker of NURTEC ODT, a dual-acting ...

Pfizer and Biohaven agreed in November to collaborate on selling the two drugs outside the U.S. At the time, Pfizer invested $350 million to acquire 2.6% of Biohaven’s common stock for $173 a share.

Biohaven common shareholders, including Pfizer, will also receive 0.5 of a share of New Biohaven, a new publicly traded company that will retain Biohaven’s non-CGRP development stage pipeline ...

Pfizer signed a partnership with Biohaven last November to commercialize Nurtec and zavegepant outside the US. At the time, the firm invested $350 million to acquire a 2.6% stake in Biohaven.

Under the terms of the agreement, Pfizer will acquire all outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in a deal tallying approximately $11.6 billion in cash ...

Pfizer will pay $148.50 in cash for each share of Biohaven, which makes Nurtec ODT for treating and preventing migraines and has a nasal spray under development.

Pfizer will acquire all the outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in cash, a 78.6% premium to Biohaven's last closing price.

FILE - A man walks by Pfizer headquarters, Friday, Feb. 5, 2021 in New York. Pfizer is spending more than $11 billion to buy the remaining portion of migraine treatment maker Biohaven ...

Pfizer first invested in Biohaven last November, according to ABC News. The company will buy all remaining shares at $148.50 per share in cash. 2.

Pfizer is starting to put its covid-19 cash influx to use by spending $11.6 billion to venture deeper into a new treatment area. ... Pfizer buying out Biohaven for $11.6B.